Beta Drugs profit and loss

·UnclassifiedChart ›

Latest FY26

Revenue: ₹385cr+6.2% on FY25
EBITDA: ₹75.7cr+1.4% on FY25
Net profit: ₹41.5cr−2.2% on FY25
EPS: ₹40.92−2.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	444	385	362
	8.5	11.2	6.4
	453	396	369
	181	174	176
	6.0	−2.6	−4.4
	76.4	68.0	34.0
	12.6	15.3	7.0
	18.1	17.2	12.5
	88.3	70.0	82.4
	383	342	307
	92.3	75.7	74.6
	74.2	58.5	62.1
Profit
	70.1	54.4	57.0
	0.0	0.0	−4.6
	70.1	54.4	57.0
	17.7	13.7	15.0
	−0.9	−0.8	−0.4
	16.8	12.9	14.6
	53.3	41.5	42.4
	53.3	41.5	—
	0.2	0.2	—
	53.5	41.7	—
Per share
	₹48.70	₹40.92	₹42.02
	₹48.70	₹40.92	₹42.02
Profit build-up — alternate / pre-Ind-AS tags
	—	—	61.5
	—	—	19.5
	—	—	42.4
Continuing & discontinued operations
	—	—	42.4
Other comprehensive income — detail
	—	0.2	—
	—	0.2	—
Per share — as-filed variants
	₹48.70	₹40.92	—
	₹48.70	₹40.92	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	257	214	191
	57.8%	55.5%	52.7%
Adjusted (ex-exceptional items) — derived
	70.1	54.4	57.0
	0.0	0.0	−4.6
	53.3	41.5	42.4
	₹48.70	₹40.92	₹42.02

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BETA₹1,849.70

Beta Drugs Limited

· Unclassified

Annual Quarterly₹ CrorePeersTHEJO MACPOWERSAKARSERVOTECHMcap ₹1,875 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	362.4	384.8	444.3
Other Income	6.4	11.2	8.5
Total Income	368.8	396.0	452.8
Expenses
+ Cost of Materials Consumed	175.8	173.8	181.3
+ Changes in Inventories	-4.4	-2.6	6.0
+ Employee Benefit Expense	34.0	68.0	76.4
+ Finance Costs	7.0	15.3	12.6
+ Depreciation & Amortisation	12.5	17.2	18.1
+ Other Expenses	82.4	70.0	88.3
Total Expenses	307.3	341.6	382.7
EBITDA	74.6	75.7	92.3
EBIT	62.1	58.5	74.2
Profit
PBT before Exceptional Items	57.0	54.4	70.1
+ Exceptional Items	-4.6	0.0	0.0
Pretax Income	57.0	54.4	70.1
+ Current Tax	15.0	13.7	17.7
+ Deferred Tax	-0.4	-0.8	-0.9
Tax Expense	14.6	12.9	16.8
Net Income	42.4	41.5	53.3
+ Net Income — Continuing Ops	—	41.5	53.3
+ Other Comprehensive Income	—	0.2	0.2
Total Comprehensive Income	—	41.7	53.5
Per Share
Basic EPS	42.02	40.92	48.70
Diluted EPS	42.02	40.92	48.70
Profit Build-up — Alternate / Pre-Ind-AS Tags
PBT before Exceptional & Extraordinary Items	61.5	—	—
+ Adjustments to Profit / (Loss)	19.5	—	—
Profit for the Period before Minority Interest	42.4	—	—
Continuing & Discontinued Operations
Profit from Continuing Operations	42.4	—	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	0.2	—
+ Items NOT to be Reclassified to P&L	—	0.2	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	40.92	48.70
Diluted EPS — Continuing Operations	—	40.92	48.70
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	191.0	213.6	256.9
Gross Margin %	52.71	55.52	57.84
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	57.0	54.4	70.1
− Exceptional Items (reconciliation)	-4.6	0.0	0.0
Net Income Adj (tax-effected)	42.4	41.5	53.3
EPS Adj	42.02	40.92	48.70
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00
Filed Debt Equity	0.71	—	—
Filed Dscr	6.90	—	—
Filed Iscr	9.15	—	—
Paid Up Equity Capital	10.1	10.1	11.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.